Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4381-4387

  Busia, Alessandra ^a   Laffranchi, Alberto ^a   Viviani, Simonetta ^a   Bonfante, Valeria ^a   Villani, Fabrizio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cardiopulmonary toxicity; Hodgkin's disease

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MECHLORETAMINE; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; BICYCLE ERGOMETER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOPULMONARY EXERCISE TEST; CARDIOTOXICITY; CONTROLLED STUDY; COUGHING; DOPPLER ECHOCARDIOGRAPHY; DYSPHAGIA; ESOPHAGITIS; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART OUTPUT; HEART PERFORMANCE; HODGKIN DISEASE; HUMAN; LUNG INJURY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEGAVOLTAGE RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; NON INVASIVE MEASUREMENT; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; REST; SPIROMETRY; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; LUNG DISEASES; MALE; MECHLORETHAMINE; MIDDLE AGED; OXYGEN CONSUMPTION; PREDNISONE; PROCARBAZINE; RADIATION INJURIES; RADIOTHERAPY; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 78650238882     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H and van Leeuwen FE: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5): 1878-1886, 2007.
2. Ng AK: Late complications after treatment for Hodgkin lymphoma. Curr Hematol Malig Rep 3(3): 119-125, 2008.
3. Sénécal D, Jais JP, Desablens B, Berthou C, Casassus P, Moles MP, Delwail V, Gastinne T, Colonna P and Andrieu JM: Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. Cancer 112(4): 846-855, 2008.
4. Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO and Prosnitz LR: Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol 24(4): 605-611, 2006.
5. Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P and Lazzarino M: Long-term events in adults patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine and adjuvant radiotherapy: a single institution 15-year follow-up. Clin Cancer Res 12(21): 6487-6493, 2006.
6. Villani F, Fede Catania A, Laffranchi A, Maffioli L, Viviani S and Bonfante V: Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease. Cancer Invest 21: 185-192, 2003.
7. Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannito E, Pavone V, Molica S, Corazza GR and Federico M: MOPPEBVCAD Chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10 years results, late toxicity and second tumors. Clin Cancer Res 12(2): 529-535, 2006.
8. Movses B, Raffin TA, Epstein AM and Link CJ: Pulmonary radiation injury. Chest 111: 1061-1076, 1997.
9. Hull MC, Morris CG, Pepine CJ and Mendenhall NP: Valvolar disfunction and carotid, subclavial and coronary artery disease in survivors of Hodgkin's lymphoma treated with radiation therapy. JAMA 290: 2831-2837, 2003.
10. Adams MJ, Hardenbergh PH, Constine LS and Lipshultz SE: Radiation associated cardiovascular disease. Critical reviews in Oncology/Haematology 45: 55-75, 2003.
11. Hirsch A, Vander Els N, Strauss DJ, Gomez EG, Leung D, Portlock CS and Yahalom J: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14: 1297-1305, 1996.
12. Aviles A, Neri N, Nambo MJ, Huerta-Guzman J, Talavera A and Cleto S: Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46: 1023-1028, 2005.
13. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR and Jacobson JS: doxorubicin, cardiac risk factors and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(19): 3159-65, 2008.
14. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F and Coiffier B: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22(10): 1864-71, 2004.
15. Nousiainen T, Jantunen E, Vanninen E and Hartikainen J: Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86(11): 1697-700, 2002.
16. Sleijfer S: Bleomycin-induced pneumonitis. Chest 120: 617-624, 2001.
17. Malik SW, Myers JL, DeRemee RA and Specks U: Lung toxicity associated with cyclophosphamide use. Haematological 85: 1032-1039, 2000.
18. Malik SW, Myers JL, DeRemee RA and Specks U: Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 154: 1851-1856, 1996.
19. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Navratil M, Pospisil Z and Vorlicek J: Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma 53: 174-181, 2006.
20. Elbl L, Vasova I, Jedlika F, Kral Z, Navratil M, Smardova L, Wagnerova B and Vorlicek J: Cardiopulmonary capacity after treatment of lymphomas in adults. Leuk Lymphoma 47: 843-851, 2006.
21. Villani F, Busia A, Villani M, Laffranchi A, Viviani S and Bonfante V: Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. Anticancer Res 29: 777-784, 2009.
22. Ogilvie CM, Forster RE, Blakemore WS and Morton JW: A standardized breath-holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 36: 1-17, 1957.
23. Cotes JE: Measurement of the transfer factor (diffusing capacity) for the lung and its subdivision. In: Lung Function, 4th ed. Boston: Blackwell Scientific Publication pp. 230-250, 1979.
24. Dinakara P, Blumenthal WS, Johnston RF, Kauffman LA and Slnick PB: The effect of anaemia on pulmonary diffusing capacity with derivation of a correct equation. Am Rev Respir Dis 102: 965-969, 1970.
25. Sahn DJ, DeMaria A, Kisslo J and Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58(6): 1072-1083, 1978.
26. Teichholz LE, Kreulen T, Herman MV and Gorlin R: Problems in echocardiographic volume determinations: echocardiographic angiographic correlations in the presence or absence of asynergy. Am J Cardiol 37(1): 7-11, 1976.
27. Connie CW: Recruitment of lung diffusing capacity: update of concept and application. Chest 122: 1774-1783, 2002.
28. Nystrom J, Celsing F, Carlens P, Ekblom H and Ring F: Evaluation of a modified acetylene rebreathing method for the determination of cardiac output. Clin Physiol 63: 201-210, 1987.
29. Kallay MC, Hyde RW, Smith RJ, Rothbard RL and Schreiner BF: Cardiac output by rebreathing in patients with cardiopulmonary diseases. J Appl Physiol 63: 201-210, 1987.
30. Liu Y, Menold E, Dullenkopf A, Reissnecker S, Lormes W, Lehmann M and Steinacker JM: Validation of the acetylene rebreathing method for measurement of cardiac output at rest and during exercise. Clin Physiol 17: 171-182, 1997.
31. Javaheri S and Sicilian L: Lung function, breathing pattern, and gas exchange in interstitial lung disease. Thorax 47: 93-97, 1992.
32. Hansen JE and Wasserman K: Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 109: 1566-1576, 1996.